Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEO-MVA-MUC1
- Development stage
- Preclinical
- Lead developer
- GeoVax Labs
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
GEO-MVA-MUC1 is a therapeutic cancer vaccine candidate developed by GeoVax Labs. It utilizes a Modified Vaccinia Ankara (MVA) viral vector platform to express abnormal, aberrantly glycosylated forms of the tumor-associated antigen Mucin 1 in the form of virus-like particles (VLPs). The vaccine is designed to stimulate an immune response against Mucin 1-expressing tumor cells, which are found in a wide range of solid tumors including breast, colon, ovarian, prostate, pancreatic, and lung cancers. Preclinical studies have shown that GEO-MVA-MUC1 can reduce tumor growth and break immune tolerance to human Mucin 1. IND-enabling studies are underway with plans for Phase 1 clinical trials[3][6][8].
- Other names
- MVA-VLP cancer vaccine
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on GEO-MVA-MUC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEO-MVA-MUC1.